BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filippone A, Lanza M, Mannino D, Raciti G, Colarossi C, Sciacca D, Cuzzocrea S, Paterniti I. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. Cancer Immunol Immunother 2022. [PMID: 35092481 DOI: 10.1007/s00262-021-03130-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Alkholifi FK, Alsaffar RM. Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. Medicina 2022;58:1572. [DOI: 10.3390/medicina58111572] [Reference Citation Analysis]
2 Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, Li S, Liang H, Xu Z, Zheng W, Wang L, Wang J, Huang X, Ting JPY, Fu Y, Lin W, Weichselbaum RR. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol 2022. [DOI: 10.1038/s41565-022-01225-x] [Reference Citation Analysis]
3 Setlai BP, Hull R, Bida M, Durandt C, Mulaudzi TV, Chatziioannou A, Dlamini Z. Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines 2022;10:682. [DOI: 10.3390/biomedicines10030682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 2022;15:24. [PMID: 35279217 DOI: 10.1186/s13045-022-01242-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]